Lercanidipine Ingen Pharma

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Ingen Pharma, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by relaxing vascular smooth muscle and lowering elevated blood pressure, thereby reducing cardiovascular risk.

GNH USA supplies Lercanidipine Ingen Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is indicated for management of arterial hypertension and works within the vascular system to lower blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. - Essential hypertension: improves vascular tone and helps achieve target blood pressure goals. - Isolated systolic hypertension: lowers elevated systolic pressure, especially in older adults.

Lercanidipine may cause a range of adverse reactions, from mild to severe. Patients should be aware of both common and rare events.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and redness, usually resolves with continued therapy. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Dizziness: sensation of light‑headedness, especially after standing. - Fatigue: generalized tiredness without obvious cause. - Tachycardia: increased heart rate, typically mild.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Angioedema: swelling of face, lips, tongue, or throat requiring emergency care. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis. - Cardiac conduction abnormalities: heart block or arrhythmias.

Before initiating therapy, clinicians should consider several safety aspects to minimise risk.

- Monitor blood pressure: check regularly after start and dose changes. - Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. - Caution in hepatic impairment: dose may need adjustment in patients with liver disease. - Use with caution in elderly: increased sensitivity to hypotensive effects. - Review concomitant medications: assess for potential drug interactions, especially CYP3A4 modulators. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Lercanidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Concurrent use with other antihypertensives: risk of excessive hypotension. - Grapefruit juice: can increase drug levels and precipitate adverse events.

Moderate Interactions (Monitor Closely): - Diuretics: additive blood‑pressure lowering, may require dose adjustment. - Beta‑blockers: combined effect on heart rate and blood pressure. - NSAIDs: may blunt antihypertensive response, necessitating closer monitoring.